Jim Lee
Company: Incyte
Job title: Head Immunology & Inflammation
Seminars:
The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis 10:15 am
day: Day One
The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis 10:15 am
The story from discovery to clinical development for a moderate to severe inflammatory skin indication Inspecting the JAK/STAT pathways critical to Incyte’s JAK inhibitor portfolio Reviewing the commercialization and market strategy of a ‘twice daily’ applied topical creamRead more
day: Day One